)

Perspective Therapeutics (CATX) investor relations material
Perspective Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Advanced radiopharmaceutical programs in neuroendocrine tumors, melanoma, and solid tumors, with updated safety/efficacy data and new patient cohorts presented at major conferences, including ASCO 2025.
Divested brachytherapy business in April 2024, recognizing a gain from discontinued operations and establishing ongoing royalty rights; now focused on radiopharmaceutical drug operations.
Expanded manufacturing footprint with new facilities in Houston, Chicago, Los Angeles, and Somerset, NJ, and invested in equipment to support clinical and future commercial supply.
Raised significant capital through multiple equity offerings, including ATM programs, private placements, and public offerings, strengthening liquidity.
Cash, cash equivalents, and short-term investments of $191.6 million as of June 30, 2025, expected to fund operations into late 2026.
Financial highlights
Net loss from continuing operations was $22.0 million for Q2 2025, compared to $11.2 million in Q2 2024; net loss for the six months ended June 30, 2025 was $39.7 million, up from $24.0 million year-over-year.
Operating expenses increased to $24.3 million in Q2 2025 from $14.8 million in Q2 2024, driven by higher R&D and G&A costs.
Research and development expenses rose to $16.6 million in Q2 2025, up 79% year-over-year, reflecting increased clinical activity and personnel.
Net cash used in operating activities was $41.5 million for the first half of 2025, compared to $4.9 million provided in the same period last year.
Cash, cash equivalents, and short-term investments totaled $192M as of June 30, 2025, down from $227M at December 31, 2024.
Outlook and guidance
Cash and investments expected to fund planned operations and clinical milestones into late 2026; management anticipates increased R&D and G&A expenses as clinical and preclinical programs advance.
Additional clinical updates for all three programs anticipated over the next 18 months.
Ongoing expansion of manufacturing capabilities to support clinical and future commercial needs.
Next Perspective Therapeutics earnings date

Next Perspective Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage